BioVex Raises $40 Million in First Close of Series F Financing

WOBURN, Mass., March 30 /PRNewswire/ -- BioVex Inc, a company developing new
generation biologics for the treatment and prevention of cancer and infectious
disease, announced today it has raised $40 million in the first close of a
series F private financing.

The placement was led by Forbion Capital Partners, who were joined by other
existing investors including Credit Agricole Private Equity, Harris & Harris
Group, Innoven Partners, New Science Ventures, Triathlon Medical Venture
Partners and Scottish Equity Partners.

Philip Astley-Sparke, President & CEO for BioVex Inc said:

"Following the unprecedented number of durable complete remissions generated
with our lead cancer product, OncoVEX GM-CSF in a Phase II study in metastatic
melanoma, the funds will be used to commence a pivotal Phase III study. The
Board is currently examining a number of options to raise a further $20
million to fund preparations for a BLA filing following the generation of
Phase III data in 2010."

The Phase III study design agreed with the FDA under a Special Protocol
Assessment (SPA) follows directly from the study design successfully employed
in Phase II. The Phase III study will also enroll previously treated patients
with unresectable Stage IIIc and Stage IV disease using OncoVEX GM-CSF as
monotherapy. Stage IIIb patients will also be eligible. The primary efficacy
endpoint will also be response rate-based; the primary objective being to
demonstrate a statistically significant increase in the rate of objective
responses maintained for six months or more, in comparison to control therapy
(subcutaneously administered GM-CSF). The study is intended to enroll 360
evaluable patients randomized such that 240 patients receive OncoVEX GM-CSF
and 120 patients receive control. BioVex plans to begin enrolling patients for
the Phase III study in the second quarter of 2009.

About OncoVEX GM-CSF Phase II Clinical Trial

BioVex recently concluded a 50-patient Phase II trial for OncoVEX GM-CSF as a
standalone therapy in patients with unresectable Stage IIIc and Stage IV
metastatic melanoma. The trial was designed to measure overall objective
response, which is defined as a complete response (CR), where disease is
completely eliminated, or partial response (PR), where there is a >50%
reduction in disease burden. 87% of patients who entered the study were
progressing after having failed prior therapy. 13 objective systemic responses
(26% objective response rate) were achieved including eight CRs. Eleven
responses have so far continued for more than 6 months (range 5-28+ months).
Responses were observed in patients with all stages of disease, including the
complete resolution of un-injected visceral deposits.

About BioVex

BioVex is a privately held biotechnology company based in Woburn, MA. The
Company is developing a new class of potent biologics for the treatment of
cancer and prevention of infectious disease.

The Company's lead cancer technology platform, OncoVEX GM-CSF is a
first-in-class oncolytic, or cancer destroying virus technology. OncoVEX
GM-CSF works by: replicating and spreading within solid tumors, causing the
death of cancer cells; while stimulating the immune system to destroy
un-injected metastatic deposits. Both modes of action have been clearly
validated in the clinic, where multiple patients with metastatic disease
progressing at enrollment have been declared disease free. BioVex believes
OncoVEX GM-CSF has the potential to become a leading standard of care in the
treatment of many solid tumors based on the strength of clinical data
generated to date, coupled with a benign side effect profile.

The Company's second program is a vaccine for genital herpes, ImmunoVEX HSV2,
which provides complete protection in animal models of the disease. The
vaccine has been authorized to commence clinical testing in the UK.

For further information, please go to www.biovex.com.

SOURCE BioVex Inc

Mr. Philip Astley-Sparke, President & CEO of BioVex Inc, +1-781-376-4913,
pastleysparke@biovex.com; or Media, Irma Gomez-Dib of FD Life Sciences,
+1-212-850-5761, irma.gomez-dib@fd.com